Webinar: Selectivity Profiling: Unbiased Analysis of Compound Selectivity in Drug Discovery

Join us in this live webinar where Drew Nager, Director of Systems Biology Oncology at Pfizer will share how CETSA Selectivity Profiling has provided insights that accelerated their projects. Laurence Arnold will present how this can be applied to a wide range of targets and through many drug discovery stages. Tove Boström will give a short introduction to CETSA and Selectivity Profiling.

Featured Speakers

Drew Nager

Director of Systems Biology

Oncology
Pfizer

Dr. Nager is part of Pfizer’s Oncology Research Unit and works on the discovery of the next generation of small-molecule, biologic, and antibody drug conjugate therapeutics. His research team leverages proteomic and transcriptomic approaches to better understand targets and candidate drugs.

Laurence Arnold

Head of R&D

Pelago Bioscience

Laurence Arnold is the Head of R&D at Pelago Bioscience. With a background in Protein biochemistry and Biophysics he and his team leverage CETSA data to determine actionable insights from cellular drug:protein interactions alongside developing the next generation of products stemming from target engagement.

Tove Boström

Product Manager

Pelago Bioscience

Tove Boström is a Product Manager at Pelago Bioscience, contributing to the development of CETSA-based solutions for drug discovery. With a strong background in proteomics and mass spectrometry, she supports the growing proteomics offering and helps turn customer needs into practical, effective applications.

Missed Our Past Webinars? Watch On-Demand

How CETSA® Enhances Translational Studies – A Sitryx Case Study 

Webinars

Bridging the Gap Between In Vitro and In Vivo Drug Discovery  Translating early-stage drug…

Uncovering Novel Modulators of PLCγ2 in Alzheimer’s Research with CETSA®

Webinars

We are pleased to present our on-demand webinar, “How CETSA® has been applied in Lead Gen…

See more